KellBenx, a New York-based company developing prenatal diagnostic tests, raised $2.5 million from four investors, according to a press release. The announcement came just days after KellBenx secured an agreement with Cedars-Sinai Medical Center to develop a new blood test designed to predict the risk of premature births early in pregnancy. The test may even work in women who are not yet pregnant, said Hassan Bennani, CEO of KellBenx, in a statement. KellBenx didn’t reveal the identities of its investors, saying only that they include three biotechnology venture capital firms and one angel investor.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
